Shangli Powder Veterinary Grade API is handled as a micronized active powder for incorporation into oral and parenteral veterinary dosage forms. Specific quantitative data for the Shangli Powder trade name are limited to the supplier certificate of analysis; the processing windows below are production-scale values commonly applied to micronized veterinary API powders of this class and must be verified against the approved dossier for each target species and country. The choice of downstream format is governed by particle-size distribution, moisture sorption, excipient compatibility, and the thermal history imposed by the manufacturing line.

Compressed Tablet Manufacture and Binder Compatibility Windows

Tablet manufacture begins with dry blending of Shangli Powder with direct-compression excipients in ratios set by the desired veterinary dose per tablet and the compressibility of the active. A formulation screen using API at 5.0 wt% to 40.0 wt% in a mixture of microcrystalline cellulose and lactose monohydrate is evaluated on an instrumented rotary tablet press fitted with 10.0 mm round flat-faced punches. The API is pre-sieved through a 0.5 mm oscillating screen; any fraction retained above 0.5 mm is re-milled with a conical mill at 2000 rpm until the D90 is below the approved dossier limit. Moisture is measured according to USP <921>; if the result exceeds 2.0%, the powder is dried at 40°C for 4 h before blending. Direct compression is acceptable when the Hausner ratio is below 1.25 and the Carr index is below 20%; higher values require wet granulation or roller compaction. Capping and lamination are observed when compaction pressure exceeds 150 MPa and binder content is below 2.0 wt%. Povidone K30 at 2.0 wt% to 4.0 wt%, added as a binder solution in a high-shear granulator with impeller speed of 300 rpm and wet massing time of 5 min, reduces capping tendency. The granules are milled through a 1.0 mm screen, dried to loss on drying below 2.0%, and lubricated with magnesium stearate at 0.5 wt% to 1.0 wt%. The final blend is compressed to hardness of 5.0–7.0 kp and friability not more than 0.8% by USP <1216>. Disintegration is controlled to less than 15 min in water at 37°C by USP <701>. Dissolution for immediate-release tablets is run with USP apparatus 2 at 50 rpm in 0.1 N HCl; the Q value is fixed by the approved dossier rather than by generic assumptions. Finished tablets are packed in aluminum/PVC blisters with moisture vapor transmission rate below 0.5 mg/day/package, and the packaged unit is held at 40°C/75% RH for 6 months to confirm physical integrity.

What Limits Fill Weight Uniformity in Veterinary Capsule Operations?

Capsule filling is limited by powder flow, electrostatic charge, and segregation of the API from filler particles. The target fill weight for a size 3 hard gelatin capsule is calculated from the dose per capsule and the tapped bulk density of the blend, but a practical upper limit is set by the body volume. A typical formulation uses direct-compression lactose or mannitol as the primary filler, sodium starch glycolate at 2.0 wt% as disintegrant, and magnesium stearate at 0.5 wt% to 1.0 wt% as lubricant. The dry blend is passed through a 0.5 mm sieve and mixed in a bin blender at 20 rpm for 15 min. Filling is performed on a tamping-pin capsule machine with pin compression adjusted from 10.0 mm to 12.0 mm; the setting is re-validated whenever the incoming API D90 changes by more than 20 µm. In low-humidity conditions below 30% RH, electrostatic charging causes powder to adhere to the dosing disc and increases fill weight RSD above 5.0%; a humidification system is required to keep the filling suite at 40–55% RH. Relative humidity above 60% can soften the gelatin shell and cause splitting on the ejection table. Fill weight variation is monitored with USP <905>; if the capsule contains less than 25 mg of active, content uniformity testing by HPLC is mandatory. The finished capsules are packed in HDPE bottles with a desiccant canister and a heat-induction seal. The format is suitable for individual animal dosing in companion animals and calves, but not for large-herd feed medication.

Injectable processing of Shangli Powder begins with a non-sterile active; therefore, the downstream manufacturer must install a sterile production train or terminal sterilization after filling. The vehicle is selected by the API’s aqueous solubility. For a poorly water-soluble veterinary active, a co-solvent system of propylene glycol and water is used, with propylene glycol typically at 10% v/v to 40% v/v and benzyl alcohol at 1.0% v/v to 2.0% v/v as a preservative. The solution is pH-adjusted to 4.5–7.5 using a citrate or phosphate buffer; the final pH must remain within ±0.3 pH units of the registered value after 24 months at 25°C. Where terminal steam sterilization at 121°C for 15 min is used, forced degradation data must show assay retention of at least 95.0% and no individual specified degradant above 0.5%. If the API is heat-labile, the solution is passed through a 0.45 µm prefilter and then a 0.22 µm PVDF sterilizing membrane, followed by filling under ISO 5 laminar flow in an ISO 7 background. Particulate matter is confirmed by USP <788> for containers of ≤ 100 mL: not more than 6000 particles at ≥ 10 µm and not more than 600 particles at ≥ 25 µm per container. Endotoxin content is controlled to not more than 0.5 EU/mg or the target animal species limit, whichever is lower, using USP <85>. The final container is Type I borosilicate glass sealed with a bromobutyl rubber stopper and crimped aluminum cap. Leachable evaluation follows ISO 10993-18 when the drug is intended for repeated injection.

For direct oral powders intended for top-dressing feed or drench administration, the primary processing objective is blend uniformity before unit dose partition. A low-shear tumble blender operating at 15 rpm for 20 min with a fill volume of 50–70% is used. The active is first geometrically diluted with dextrose monohydrate or lactose at a 1:9 ratio before adding to the main blender to minimize active segregation. Blend uniformity is sampled at 10 points with a powder thief; the relative standard deviation of the API assay should not exceed 5.0%. If the RSD exceeds 5.0%, mixing time is extended in 5-min increments until the criterion is met, but total mixing time should not exceed 40 min because overblending can cause particle attrition and increase fine-particle carryover. Individual powder doses are filled into sachets with a weight tolerance of ±5.0% for doses above 500 mg and ±10.0% for doses below 200 mg. The sachet material is a PET/aluminum/LDPE laminate with a puncture resistance of at least 8.0 N by ASTM F1306 and a water vapor transmission rate below 0.1 g/m²/day. These powders are intended for short-duration oral administration to swine, poultry, or cattle; they are not sterile and are not formulated for parenteral use.

When Granulation Is Required to Reduce Dusting Losses in Feed Additive Lines

Granulation of Shangli Powder is chosen when dusting loss exceeds 1.0 mg/m³ during powder transfer or when bridging in a rotary valve hopper disrupts dose partition. Dry granulation is run on a roller compactor at roll pressure of 40 bar to 80 bar with a 1.0 mm screen; the compaction force is adjusted to produce granules with a Hausner ratio below 1.25 after milling. Wet granulation is preferred for low-dose formulations where content uniformity is difficult to achieve by simple blending. Purified water or an aqueous HPMC E5 binder solution is sprayed at 8–12 wt% of the dry mass in a high-shear granulator with impeller speed of 250 rpm and chopper speed of 1500 rpm. The wet mass is dried in a fluid-bed dryer at inlet temperature of 60°C until the loss on drying is not more than 2.0%; the dried granules are sieved to collect the 0.150–0.850 mm fraction. HPMC E5 at 3.0 wt% increases granule strength and reduces dust without significantly delaying disintegration; alternative binders such as povidone may be used but require dissolution verification because povidone can interact with certain anionic veterinary actives. The terminal granules are filled into laminated foil pouches under nitrogen flush when oxidation is a known degradation pathway. Particle size distribution is checked by sieving according to USP <786>; the retained mass on the 0.850 mm sieve should not exceed 10.0% and the fines passing 0.150 mm should not exceed 15.0%. Final product is packaged in sachets or metering scoops for oral administration via feed.

Downstream format compliance matrix for Shangli Powder Veterinary Grade API:

Flush the Mixer Only After LC-MS/MS Confirmation

Premix production shifts the risk from dosage uniformity to cross-batch drug carryover. The API is diluted with calcium carbonate, ground rice hulls, or corn cob to a target concentration of 10 mg/g to 200 mg/g, depending on the approved species claim and the diluent’s particle size. Mixing is performed in a ribbon blender at 20 rpm for 15 min, with the fill volume set at 70% of gross capacity. A geometric pre-blend is required when the formulation contains less than 1.0 wt% active before final dilution. The finished premix is discharged through a rotary airlock into 20 kg multi-wall paper sacks with polyethylene liners. The product is labeled under 21 CFR 501 subpart B for animal feed use. The most critical operation rule is sequencing when ionophore coccidiostats are run on the same line. Equine exposure to monensin from residual premix is a known fatality risk; therefore, premix lines that handle ionophores must follow a flush procedure with ground corn or soybean meal. The flush batch is assayed by LC-MS/MS for the ionophore, and the equipment is not cleared until the result is below the validated reporting limit of the residue method. A formal cross-contamination validation is required under 21 CFR 558.3 and 21 CFR 225.1. In a multi-product facility, a separate mixing line or a documented conveyor and elevator cleaning protocol is used for non-ruminant products. Electrostatic dust collection at transfer points is maintained below 0.5 mg/m³ to reduce both product loss and environmental carryover. Batch-to-batch carryover of the API itself is controlled by cleaning validation with swab limits based on the lowest approved dose and the next product’s maximum daily intake.

Ready-to-use oral solutions containing Shangli Powder are formulated when the target species cannot be dosed by solid oral forms, such as poultry or swine during mass treatment via drinking water. The API is dissolved or suspended in a vehicle at a concentration fixed by the label dose, for example 100 mg/mL, but the actual ratio is product-specific and must be stable in hard water. The formulation is buffered with citrate to pH 4.0–5.5; if the API is a weak base, lower pH increases solubility but may accelerate hydrolysis, so a forced degradation matrix is used to select the pH. Chloride ion content is limited if the active is susceptible to acid-catalyzed degradation; light-sensitive formulations are packed in amber HDPE or PET bottles with an opaque child-resistant cap. Manufacturing takes place in an ISO 7 area with a 0.45 µm clarification filter for bulk solution, but this format is not sterile unless specifically registered as such. Leachable testing follows USP <661.1> for plastic packaging systems, and fill volume is checked according to USP <698> for liquid-filled containers. Drinking-water stability is tested by diluting one dose into 1 L of water containing 250 mg/L calcium carbonate at 25°C for 24 h; a turbidity increase above 5 NTU or visible precipitate fails the formulation. Terminal pH drift over shelf life is controlled at ±0.3 pH units from the release value. The final product is labeled for oral use only, with a beyond-use date after opening when the preservative system supports multi-day use.